fold

Fulcrum Therapeutics Announces Positive Initial Results from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease at the 67th American Society of Hematology Annual Meeting

December 06, 2025 17:30 ET | Source: Fulcrum Therapeutics, Inc. ― Clear dose-response observed, with a robust and clinically meaningful…

3 weeks ago

Baker Tilly ASA India, a leading homegrown professional services firm with 8 offices and more than 1,200 professionals nationwide, announced…

2 months ago

Baker Tilly ASA India, a leading homegrown professional services firm with 8 offices and more than 1,200 professionals nationwide, announced…

3 months ago

Rolls Out GCC 2.0 Service Line to Unlock Long-term Value for Enterprises MUMBAI, India and LONDON and ISELIN, N.J., July…

5 months ago